A study published in the August 1 issue of the Journal of Infectious Diseases has shown for the first time that RTS,S, the world’s most clinically advanced malaria vaccine candidate, maintains protection during a 45 month follow-up period. The study conducted in 2022 Mozambican children age 1-4 years demonstrates that the RTS,S/AS02 vaccine is capable of reducing clinical episodes of malaria by 30 percent and severe malaria cases by 38 percent for at least 45 months following its administration.

For further information: http://blog.hospitalclinic.org/en/2009/10/el-candidat-a-vacuna-contra-la-malaria-rtss-mostra-eficacia-a-llarg-termini-en-nens/